A San Francisco Bay Area-based biopharmaceutical company has again been made an example of in the Court of Chancery, with Chancellor Kathaleen McCormick finding its tactics in a Section 220 case were egregious enough to warrant paying more than $1.7 million in plaintiffs’ attorney fees.
McCormick’s six-page opinion repeatedly calls conduct by Gilead Sciences Inc. and its Potter Anderson & Corroon and Cooley counsel “glaringly egregious” and starts off with a reference to the court’s right to shift fees to deter abusive litigation, citing Gilead’s actions before and during the case as well within the scope of that right.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]